Treatment of pancreatic cancer: Current limitations, future possibilities

ONCOLOGY

Volumn 10, Issue 3, 1996, Pages 301-307

  William Blackstock, A ^a   Cox, Adrienne D ^b   Tepper, Joel E ^c  

^a Department of Radiation Oncology ^*  (United States)

^b Depts Radiat Oncol and Pharmacol

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACLARUBICIN; ANTIESTROGEN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CANCER VACCINE; COFERON A; DIHYDROXYANTHRACENEDIONE DIACETATE; DOCETAXEL; ENZYME INHIBITOR; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; GANCICLOVIR; GEMCITABINE; GONADORELIN AGONIST; IMMUNOMODULATING AGENT; INTERLEUKIN 2; LEUPRORELIN; MEGESTROL ACETATE; MITOMYCIN; MONOCLONAL ANTIBODY; OCTREOTIDE; PACLITAXEL; PHOSPHORUS 32; PIRARUBICIN; RADIOPHARMACEUTICAL AGENT; RECOMBINANT ALPHA2A INTERFERON; SOMATOSTATIN DERIVATIVE; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; HUMAN; PANCREAS CANCER; REVIEW;

FORECASTING; GENE THERAPY; HORMONES; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY; PANCREATIC NEOPLASMS;

EID: 15844426340     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Gudjonsson B: Cancer of the pancreas. Cancer 60:2284-2303, 1987.
2. National Cancer Institute Annual Cancer Statistics Review 1973-1988. Bethesda, Maryland, Department of Health and Human Services, 1991.
3. Parkin D, Pisani P, Ferlay J: Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54.594-606, 1993.
4. Douglass H: Adjuvant therapy for pancreatic cancer. Woild J Surg 19:170-174, 1995.
5. American Cancer Society Cancer Facts and Figure - 1991. American Cancer Society, 1991.
6. Connolly M, Dawson P, Michelassi F, et al: Survival in 1001 patients with carcinoma of the pancreas. Ann Surg 206:366-373, 1987.
7. Singh S, Longmire W, Reber H: Surgical palliation for pancreatic cancer: The UCLA experience. Ann Surg 212:132-193, 1990.
8. Shibamoto Y, Manabe T, Baba M, et al: High dose, external beam and intraoperative radiotherapy in the treatment of resectable pancreatic cancer, Int J Radiat Oncol Biol Phys 19:605-611, 1990.
9. Steele G, Osteen R, Winchester D, et al: Clinical highlights from the national cancer data base:1994. CA Cancer J Clin 44(2):71-80, 1994.
10. Yeo C, Cameron J, Lillemoe K, et al: Pancreaticoduodenectomy for cancer of the head of the pancreas. Ann Surg 221(6).721-733, 1995.
11. Cameron J, Crist D, Yeo C, et al: One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann Surg 217:430-438, 1993.
12. Crile G. The advantages of bypass operations over radical pancreaticoduodenectomy in the treatment of pancreatic carcinoma. Surg Gynecol Obstet 130:1049-1053, 1970.
13. Haslam J, Cavanaugh P. Stroup S Radiation therapy in the treatment of irresectable adenocarcinoma of the pancreas. Cancer 32:1341-1345, 1973
14. Gastrointestinal Tumor Study Group: Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone J Natl Cancer Institut 80(10).751-755, 1988.
15. Carter S, Comis R: Adenocarcinoma of the pancreas: Prognostic variable and criteria of response, in Staquet M (ed): Cancer Therapy. Prognostic Factors and Criteria of Response, pp 237-253. New York, Raven Press, 1975.
16. Brennen M, Kinsella T, Friedman M: Cancer of the Pancreas, in Hellman S, Rosenberg SA, Devita VT (eds): Cancer Principles and Practice of Oncology, 3rd Ed, pp 800-835 Philadelphia. JB Lippincott, 1989
17. Bukowski RM, Abderhalden RI, Hewlet JS, et al: Phase II trial of streptozotocin, mitomycin C, and 5-fluorouracil in adenocarcinoma of the pancreas. Cancer Clin Trials 3:321, 1980.
18. Smith FP, Hoth DF, Levin B, et al: 5-fluorouracil, adriamycin and mitomycin C chemotherapy for advanced adenocarcinoma of the pancreas. Cancer 46:2014-2018, 1980.
19. Palmer K, Kerr M, Cull A: Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 81:882-885, 1994.
20. Tepper J, Nardi G, Suit H, et al: Carcinoma of the pancreas: Review of MGH experience from 1963 to 1973 - Analysis of surgical failure and implications for radiation therapy. Cancer 37:1519-1524, 1976
21. Gastrointestinal Tumor Study Group: Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 59.2006-2010, 1987.
22. Douglass HO, Strablein DM: Ten year follow-up of first generation surgical adjuvant studies of the Gastrointestinal Tumor Study Group, in Salmon SE (ed): Adjuvant Therapy of Cancer TV, pp 405-415. Philadelphia, WB Saunders, 1990.
23. Whittington R, Bryer MP, Haller DG. et al: Adjuvant therapy of resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 21:1137, 1991.
24. Thomas F, Krall J, Hendrickson F, et al: Evaluation of neutron irradiation for pancreatic cancer Am J Clin Oncol 12 283-289, 1989.
25. Perez T, Nori D, Hilaris B, et al: Treatment of primary unresectable carcinoma of the pancreas with I-125 implantation. Int J Radiat Oncol Biol Phys 17:931-935, 1989.
26. Dobelbower R, Howard J, Bagne F, et al: Treatment of cancer of the pancreas by precision high dose (PHD) external photon beam and intraoperative electron beam therapy (IOEBT). Int J Radiat Oncol Biol Phys 16:205-209, 1989.
27. Tepper J E, Noyes D, Krall J M, et al: Intraoperative radiation therapy of pancreatic carcinoma: A report of RTOG-8505, Int J Radiat Oncol Biol Phys 21 (5):1145-1149, 1991.
28. Gyr KE, Meier R: Pharmacodynamic effects of sandostatin in the gastrointestinal tract Metabolism 41:17-21, 1992.
29. Weckbecker G, Raulf F, Stolz B, et al: Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther 66:245-264, 1993.
30. Szende B, Zalatnai A, Schally AV, et al: Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone (LH-RH) and somatostatin. Proc Natl Acad Sci USA 86:1643-1647, 1989.
31. Friess H, Buchler M, Beglinger C, et al: Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer. Pancreas 8:540-545, 1993.
32. Klijn JG, Hoff AM, Planting AS, et al: Treatment of patients with metastatic pancreatic and gastrointestinal tumors with somatostatin analogue Sandostatin: a phase II study including endocrine effects. Br J Cancer 62:627-630, 1990.
33. Ebert M, Friess H, Beger H, et al: Role of octreotide in the treatment of pancreatic cancer Digestion 55(suppl 1):48-51, 1994.
34. Weiss M, Kelsten M: Biologic markers of breast cancer prognosis, in Fowble B, Glick J, Rosato E (eds). Breast Cancer Treatment: A Comprehensive Guide to Management, pp 209-242 St. Louis. Mosby Year Book, 1991.
35. Berz C, Hollander C, Miller B, et al: Endocrine responsive pancreatic carcinoma sterior binding and cytoxicity studies in human tumor cell lines. Cancer Res 446:2276-2281, 1986.
36. Taylor OM, Benson EA, McMahon MJ, et al: Clinical trial of tamoxifen inpatients with irresectable pancreatic adenocarcinoma: The Yorkshire Gastrointestinal Tumor Group. Br J Surg 80(3): 384-386, 1993.
37. Wong A, Chan A: Survival benefit of tamoxifen therapy in adenocarcinoma of pancreas. Cancer 71:2200-2203, 1993.
38. Rosenberg L, Barkun A, Denis M, et al: Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas Cancer 75(1):23-28, 1995.
39. Szende B, Srkalovic G, Schally AV, et al: Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancer in hamster, events that accompany regression. Cancer 65.2279-2290, 1990.
40. Redding TW, and Schally AV: Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc Natl Acad Sci USA 81.248-252, 1984.
41. Zaniboni A, Meriggi F, Arcangeli G, et al: Leuprolide and tamoxifen in the treatment of pancreatic cancer, a phase II study. Eur J Cancer 30:128, 1994.
42. Rosenstein M, Yron I, Kaufmann Y, et al: Lymphokine-activated killer cells; lysis of fresh synergistic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. Cancer Res 44:1946-1953, 1984.
43. Yron I, Brahmi Z, Spiess P J, et al: In vitro growth of murine T cells: V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J Immunol 125:238-245, 1980.
44. Rosenberg SA, Lotze MT, Muul LM, et al: A progress report on the treatment of 157 patients with advanced cancer using LAK cells and IL-2 or high dose IL-2 alone. N Engl J Med 316:889-897, 1987.
45. Takahashi K, Nakamura T, Koyanagi M, et al: A murine very late activation antigen-like extracellular matrix receptor involved in CD-2 and lymphocyte function-association antigen-1-independent killer-target cell interaction. J Immunol 145:4371-4379, 1990.
46. Takahashi T, Ishikura H, Iwai K, et al. Cytokine regulation of cell-to-cell interactions in lymphokine-activated killer cell cytoxicity in vitro. Cancer Immunol Immunother 36:76-82, 1993.
47. Sparano JA, Fisher RI, Weiss GR. et al: Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors. J Immunol 16:216-223, 1994.
48. Kantor J, Irvine K, Abrams S, et al: Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst 84:1084-1091, 1992
49. DiMaio JM, Clary BM, Via DF, et al: Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery 116:205-213, 1994
50. O'Connel M: Current status of chemotherapy for advanced pancreatic and gastric cancer. J Clin Oncol 3.1032-1039, 1985.
51. Harter W, Dritschilo A: Cancer of the pancreas: Are chemotherapy and radiation appropriate? Oncology 3(6):27-30, 1989.
52. Marsh RD, Manyam V, Bewsher C, et al: Circadian rhythm modulated 5-FUdR infusion with megace in the treatment of advanced pancreatic cancer. J Surg Oncol 57:25-29, 1994.
53. Pazdur R, Ajani JJ, Abbruzzese JL, et al: Phase II evaluation of fluorouracil and recombinant -2α interferon in previously untreated patient with pancreatic adenocarcinoma. Cancer 70.2073-2076, 1992.
54. Bernhard H, Jager-Arand AE, Bernhard G, et al: Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid, and Interferon alpha-2a: Results of a phase II trial. Br J Cancer 71:102-105, 1995.
55. Scheithauer W, Pfeffel F, Kornek G, et al: A phase II trial of 5-FU, leucovorin and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreas. Cancer 70:1864-1866, 1992.
56. Chandrasekaran B, Kute T, Duch D: Synchronization of cells in S phase of the cell cycle by 3′-azido-3′-deoxythymidine: Implications for cell cytotoxicity. Cancer Chemother Pharmacol 35:489-495, 1995
57. Mondher M, Rougier P, Oliviera J, et al: Phase II trial of pirarubicin in the treatment of advanced pancreatic cancer. Cancer Invest 12(4):403-405, 1994.
58. Asbury R, Cnaan A, Johnson L, et al: An Eastern Cooperative Oncology Group, phase II study of single agent DHAD, VP-16, aclacinomycin, or spirogermanium in metastatic pancreatic cancer. Am J Clin Oncol 17(2):166-169, 1994.
59. Moore M, Anderson J, Burris H, et al: A randomized trial of gemcitabine (GEM) versus 5-FU as a first-line therapy in advanced pancreatic cancer Proc Am Soc Clin Oncol 14:199, 1995.
60. Brown T, Tangen C, Fleming T, et al: A phase II trial of taxol and G-CSF in patients with adenocarcinoma of the pancreas. Proc Am Soc Clin Oncol 12:200, 1993.
61. Rougier P, De Forin F M, Ademis A, et al: Phase II study of taxotere in pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 13:200, 1994.
62. Larson SM, Cheung NK, Leibel SA: Radioisotope conjugates biologic therapy of cancer, in DeVita VT, Rosenberg SA (eds): Biologic Therapy of Cancer, pp 496-511. Philadelphia, JB Lippincott, 1991.
63. Order SE, Siegel JA, Lustig RA, et al: Infusional brachytherapy in the treatment of pancreatic cancer: A new radiation modality (Preliminary report of the phase I study). Anti Immunoconj Radiopharm 7(1):11-27, 1994.
64. Shirasawa S, Furuse M, Yokoyama N, et al: Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260:85-88, 1993
65. Goyette MC, Cho K, Fasching CL, et al: Progression of colorectal cancer is associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer. Mol Cell Biol 12:1387-1395, 1992
66. Berrozpe G, Schaeffer J, Peinado MA, et al: Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer, Int J Cancer 58:185-191, 1994
67. Lumadue JA, Griffen CA, Osman M, et al: Familial pancreatic cancer and the genetics of pancreatic cancer. Surg Clin N Amer 75 (5):845-855, 1995.
68. Capella G, Cronauer-Mitra S, Pienado MA, et al: Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. Envir Health Perspect 93:125-131, 1991.
69. Smith MR, DeGudicibus SJ, and Stacey DW: Requirement for c-ras proteins during viral oncogene transformation. Nature 320:540-543, 1986.
70. Gura T: Antisense has growing pains. Science 270:575-577, 1995
71. Carter G, Gilbert C, Lemoine NR: Effects of antisense oligonucleotides targeting K-ras expression in pancreatic cancer cell lines. Int J Oncol 6:1105-1112, 1995.
72. Aoki K, Yoshida T, Sugimura T, et al: Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the marine peritoneal cavity. Cancer Res 55:3810-3816, 1995
73. Cox AD, Der CJ: Protein prenylation: More than just glue? Curr Opin Cell Biol 4:1008-1016, 1992.
74. Sun J, Qian Y, Hamilton AD, et al. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-ras mutation and p53 deletion. Cancer Res 55:4243-4247, 1995.
75. Nagasu T, Yoshimatsu K, Rowell C, et al: Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res 55:5310-5314, 1995.
76. Kohl NE, Omer CA, Conner MW, et al: Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nature Med 1:792-797, 1995.
77. Sepp-Lorenzino L, Ma Z, Rands E, et al. A peptidomimetic inhibitor of farnesyl: Protein transferase blocks the anchorage-dependent and independent growth of human tumor cell lines. Cancer Res 55: 5302-5309, 1995.
78. Nagasu T, Yoshimatsu K, Rowell C, et al: Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res 55.5310-5314, 1995.
79. James GL, Goldstein JL, Brown MS: Polylysine and CVIM sequences of K-ras4B dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem 270:6221-6226, 1995.
80. Prendergast GC, Davide JP, deSolms SJ, et al: Famesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol 14:4193-4202, 1994.
81. Ura H, Obara T, Nishino N, et al: Cytotoxicity of simvastatin to pancreatic adenocarcinoma cells containing mutant ras gene. Jpn J Cancer Res 85:633-638, 1994.
82. Sumi S, Beauchamp RD, Townsend CM, et al: Lovastatin inhibits pancreatic cancer growth regardless of ras mutation. Pancreas 9:657-661, 1994.
83. DeClue JE, Vass WC, Papageorge AG, et al: Inhibition of cell growth by lovastatin is independent of ras function. Cancer Res 51:712-717, 1991.
84. Moertel C, Childs D, Reitemeier R, et al: Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2(626):865-867, 1969.
85. Moertel C, Frytak S, Hahn R, et al: Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil). and high dose radiation + 5-fluorouracil. Cancer 48(8):1705-1710, 1981.
86. Gastrointestinal Tumor Study Group: Radiation therapy combined with adriamycin or 5-fluorouracil for the treatment of locally unreseciable pancreatic carcinoma. Cancer 56:2563-2568, 1985.
87. Klassen DJ, Maclntyre JM, Catton GE, et al: Treatment of locally unresectable cancer of the stomach and pancreas: A randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil: An Eastern Cooperative Oncology Group study. J Clin Oncol 3:373-378, 1985